Data availability
The data that support the findings of this study are available from the corresponding authors upon reasonable request.
Acknowledgments
Supported by Pfizer and BioNTech. We thank colleagues at Pfizer, BioNTech, and UTMB for helpful discussions and support during the study. We thank the Pfizer-BioNTech clinical trial C4591001 participants, from whom the post-immunization human sera were obtained. We thank the many colleagues at Pfizer and BioNTech who developed and produced the BNT162b2 vaccine candidate. P.-Y.S. was supported by NIH grants AI142759, AI134907, AI145617, and UL1TR001439, and awards from the Sealy & Smith Foundation, Kleberg Foundation, the John S. Dunn Foundation, the Amon G. Carter Foundation, the Gilson Longenbaugh Foundation, and the Summerfield Robert Foundation.
Author contributions
Conceptualization, X.X., V.D.M., S.W., P.-Y.S.; Methodology, X.X., J.Z., C.R.F.G., H.X., P.-Y.S; Investigation, X.X., J.Z., C.R.F.G., H.X., K.A.S., D.C., P.R.D., P.-Y.S; Resources, M.C., D.C., P.R.D., P.-Y.S; Data Curation, X.X., J.Z., C.R.F.G., P.-Y.S; Writing-Original Draft, X.X., P.-Y.S; Writing-Review & Editing, X.X., P.R.D., P.-Y.S.; Supervision, X.X., M.C., D.C., P.R.D., P.-Y.S.; Funding Acquisition P.-Y.S.
Competing financial interests
X.X., V.D.M., and P.-Y.S. have filed a patent on the reverse genetic system. K.A.S., M.C., D.C., and P.R.D. are employees of Pfizer and may hold stock options. X.X., J.Z., C.R.F.G., H.X., and P.-Y.S. received compensation from Pfizer to perform the neutralization assay.